An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, says a team led by Dr. Dan Landau (Dan Landau) and researchers at NY Genome Center and Memorial Sloan Kettering Cancer Center. bit.ly/45pXCJ3

A major problem with cell-free tumor DNA to detect cancer (Liquid biopsy) is its very low quantity. Today Nature Medicine use of #AI to overcome that issue with impressive results for radical signal-to-noise enrichment nature.com/articles/s4159… free access rdcu.be/dKNOx

parts per million -> parts per billion -> parts per trillion? how low can we go with ctDNA detection in the era of dirt cheap whole genomes ?? .. momentous milestone by Adam Widman Dan Landau & team👇👇👇

#NESTTrial 🪺 responses to date.🙌🏾 What’s particularly of note is the deepening of the responses with longer time to brew 🫖. The pattern🌊 and lack of recurrence speaks to curative potential of immunotherapy for both MSS and MSI-High tumors. #CRCSM ESMO - Eur. Oncology #ESMOGI24 OncoAlert

Congrats to Josh and team!

Congrats Nico and Will and Bishoy and team!

Thanks Amanda Frydendahl Boll Johansen and Claus Lindbjerg Andersen for leading here! Very excited to see this out in print

The integration of duplex sequencing with cost-effective Ultima sequencing enhances the accuracy of whole-genome circulating cell-free DNA profiling. Dan Landau Alexandre Pellan Cheng nature.com/articles/s4159…

How do you scale up liquid biopsy for use in routine cancer monitoring? Combine plasma-only ultrasensitive detection with cheap sequencing and a simple lab workflow. A big thanks to Alexandre Pellan Cheng for pushing this work over the finish line! Stay tuned and more to come